Marker for predicting or diagnosing qi-blood barrier inflammatory injury caused by SARS-CoV-2 and application
Through proteomics and metabolomics, VCL and ICAM-1 pathways are found to have a key role in SARS-CoV-2 infection, providing markers and detection methods, and solving the detection of inflammatory damage of qi and blood barriers in infection with Omickron mutant strains. The problem has achieved accurate prediction and diagnosis of inflammatory damage to the qi and blood barrier, and promoted disease prevention and treatment.
Patent Information
- Application Number
- CN202411160582.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to accurately detect and predict inflammatory damage to the qi-blood barrier caused by SARS-CoV-2, especially in infection with the Omickron variant, which leads to blurred disease characteristics and unknown potential damage mechanisms in low-risk populations, affecting disease assessment. and prevention strategies.
Through proteomics and metabolomic comparisons, the VCL and ICAM-1 pathways were found to be key players in the inflammation-adhesion-exhaustion mechanism in SARS-CoV-2 infection, providing for the prediction or diagnosis of inflammatory qi and blood barriers. Markers of damage, including detection of VCL and ICAM-1 expression, and construction of predictive or diagnostic models and devices.
Effectively predict or diagnose inflammatory damage to the qi and blood barrier, promote prevention and treatment strategies, reduce lung exudation and barrier damage, improve oxygenation and reduce clinical mortality.
Smart Images

Figure CN119064591A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection technology and relates to a marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 and its application. Background Art
[0002] The SARS-CoV-2 virus has undergone many mutations, with the Omicron strain currently being the most prevalent worldwide. Studies have shown that different SARS-CoV-2 strains that initially focused on the respiratory system can also affect various extrapulmonary systems. Therefore, employing a multi-omics study based on the hematological ecosystem and utilizing a collaborative multi-method validation approach allowed us to accurately capture the comprehensive pathological landscape of SARS-CoV-2.
[0003] Compared with the wild-type (WT) variant, the Omicron variant has approximately two times the affinity for ACE2, making it more transmissible. In terms of respiratory symptoms, Omicron is almost indistinguishable from early variants and is relatively milder than some early strains. However, the infection characteristics of Omicron show high heterogeneity, with symptoms ranging from asymptomatic to severe pneumonia, respiratory distress, organ dysfunction, and even death in individuals of all age groups. Therefore, understanding the pathogenic mechanism of Omicron remains a central focus of research. Another study confirmed that damage to the blood-gas barrier during hospitalization or persistent lung function impairment after discharge is the main cause of refractory hypoxemia, but the mechanism is unclear. In addition, the vague disease characteristics in low-risk populations pose a challenge to assessing the progression of Omicron. There is still controversy about the definition of asymptomatic Omicron, and some believe that both asymptomatic and symptomatic Omicron infection can trigger a humoral immune response. At present, the mechanism mediating the chemotaxis of inflammatory cells is also unclear. Therefore, although Omicron variants are generally considered to be less severe, revealing potential pathways of damage in the Omicron hematological ecosystem and identifying key targets for effectively blocking blood-gas barrier extravasation pathways may enhance oxygenation and reduce clinical mortality.
[0004] SARS-CoV-2 triggers inflammatory damage to the blood-gas barrier, and accurate detection of symptoms provides valuable insights into the associated disease mechanisms, which can advance strategies for preventing and treating subsequent diseases. Summary of the invention
[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a marker and application for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, wherein the marker includes VCL and / or ICAM-1.
[0008] This study used proteomics and metabolomics to compare infection with wild-type (WT) SARS-CoV-2 and Omicron strains. The study found that WT infection causes severe inflammation affecting multiple systems, while Omicron causes milder symptoms even in asymptomatic cases. The VCL / ICAM-1 pathway has emerged as a key player in the inflammation-adhesion-exudation mechanism and is essential for maintaining the blood-air barrier. Inhibition of this pathway can reduce lung exudation and barrier damage. The detection of VCL and ICAM-1 can effectively predict or diagnose SARS-CoV-2-induced inflammatory damage to the blood-air barrier, which can advance strategies for preventing and treating subsequent diseases.
[0009] In a second aspect, the present invention provides a marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 as described in the first aspect, or a reagent for detecting the expression amount of the marker as described in the first aspect, in the preparation of a product for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2.
[0010] Preferably, the application includes constructing a prediction or diagnosis model for SARS-CoV-2-induced inflammatory damage to the air-blood barrier and / or preparing a prediction or diagnosis device for predicting or diagnosing SARS-CoV-2-induced inflammatory damage to the air-blood barrier.
[0011] In a third aspect, the present invention provides a product for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, characterized in that the product comprises reagents and / or equipment for detecting the relative expression level of the marker described in the first aspect.
[0012] Preferably, the product comprises a kit.
[0013] In a fourth aspect, the present invention provides a prediction or diagnosis model for inflammatory damage to the air-blood barrier caused by SARS-CoV-2, wherein the input variables of the prediction or diagnosis model for inflammatory damage to the air-blood barrier caused by SARS-CoV-2 include the expression levels of the markers for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 as described in the first aspect.
[0014] Preferably, the output variables of the prediction or diagnosis model of inflammatory damage to the air-blood barrier caused by SARS-CoV-2 include differential expression folds,
[0015] The calculation formula of the differential expression fold is as follows:
[0016]
[0017] Preferably, the criteria for judging inflammatory damage to the air-blood barrier caused by SARS-CoV-2 are:
[0018] The differential expression fold of the VCL is ≥1, and the differential expression fold of the ICAM-1 is ≥1.
[0019] In a fifth aspect, the present invention provides a device for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, the device comprising a detection unit and an analysis unit;
[0020] The detection unit is used to perform the following steps: detecting the expression level of a combination of biomarkers for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 in a sample of an individual to be tested;
[0021] The analysis unit is used to perform the following steps:
[0022] The detection results of the biomarkers used to predict or diagnose SARS-CoV-2-induced inflammatory damage to the air-blood barrier are input into the prediction or diagnosis model for SARS-CoV-2-induced inflammatory damage to the air-blood barrier described in the fourth aspect for data analysis, and the prediction probability is output to determine whether the SARS-CoV-2-induced inflammatory damage to the air-blood barrier is positive.
[0023] Preferably, the sample comprises serum.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] This study used proteomics and metabolomics to compare WT and Omicron SARS-CoV-2 infection. The study found that WT infection causes severe inflammation affecting multiple systems, while Omicron causes milder symptoms even in asymptomatic cases. The VCL / ICAM-1 pathway has emerged as a key player in the inflammation-adhesion-exudation mechanism and is essential for maintaining the blood-air barrier. Inhibition of this pathway can reduce lung exudation and barrier damage. The detection of VCL and ICAM-1 can effectively predict or diagnose SARS-CoV-2-induced inflammatory damage to the blood-air barrier, which can advance strategies for preventing and treating subsequent diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1These are the test results of routine blood indicators, where Figure A is the WBC test result, Figure B is the NEU test result, Figure C is the LYM test result, Figure D is the MONO test result, Figure E is the CRP test result, Figure F is the NEU% test result, Figure G is the LYM% test result, and Figure H is the MONO% test result; HC represents healthy human serum samples, OA represents serum samples of asymptomatic Omicron infection patients, OS represents serum samples of symptomatic Omicron infection patients, and WT represents serum samples of SARS-CoV-2 infected patients.
[0027] Figure 2 These are the test results of biochemical indicators, where Figure A is the BUN test result, Figure B is the GLU test result, Figure C is the Cr test result, and Figure D is the Ca test result. HC represents the serum sample of a healthy human, OA represents the serum sample of an asymptomatic Omicron infection patient, OS represents the serum sample of an Omicron symptomatic infection patient, and WT represents the serum sample of a SARS-CoV-2 infected patient.
[0028] Figure 3 These are the thrombin index test results, where A is the APTT test result, B is the DD test result, C is the FIB test result, D is the PT test result, E is the MYO test result, F is the LDH test result, G is the CK test result, and H is the AST test result, where HC represents healthy human serum samples, OA represents serum samples of asymptomatic Omicron infection patients, OS represents serum samples of symptomatic Omicron infection patients, and WT represents serum samples of SARS-CoV-2 infected patients.
[0029] Figure 4 These are the results of blood gas analysis, where A is the pH test result, B is the Hb test result, C is the MetHb test result, D is the Hct test result, E is the SBE test result, and F is the SBC test result. HC represents the serum sample of a healthy human, OA represents the serum sample of an asymptomatic Omicron infection patient, OS represents the serum sample of an Omicron symptomatic infection patient, and WT represents the serum sample of a SARS-CoV-2 infected patient.
[0030] Figure 5are the test results of lymphocyte subset indicators, among which Figure A is the test result of CD3+CD8+, Figure B is the test result of CD3-CD19+, Figure C is the test result of CD3-CD15+, Figure D is the test result of CD4+CD8+, Figure E is the test result of CD3+CD4+, Figure F is the test result of CD3+CD45+, Figure G is the test result of CD3+CD56+CD16+, Figure H is the test result of CD3+CD56+CD16+%, Figure I is the test result of CD3-CD16+56+%, and Figure J is the test result of CD3-CD16+56+, among which HC represents the serum sample of healthy human body, OA represents the serum sample of Omicron asymptomatic infection, OS represents the serum sample of Omicron symptomatic infection, and WT represents the serum sample of SARS-CoV-2 infected person.
[0031] Figure 6 This is a test flow chart of Example 2.
[0032] Figure 7 It is a heat map result showing the overall data characteristics.
[0033] Figure 8 Figure 3 is the analysis result of differentially expressed proteins among the groups, among which Figure A shows the differentially expressed proteins between asymptomatic Omicron infection patients and healthy people, Figure B shows the differentially expressed proteins between symptomatic Omicron infection patients and healthy people, Figure C shows the differentially expressed proteins between symptomatic Omicron infection patients and asymptomatic Omicron infection patients, Figure D shows the differentially expressed proteins between SARS-CoV-2 infection patients and healthy people, Figure E shows the differentially expressed proteins between asymptomatic Omicron infection patients and SARS-CoV-2 infection patients, and Figure F shows the differentially expressed proteins between symptomatic Omicron infection patients and SARS-CoV-2 infection patients.
[0034] Fig. 9 This is the result of GO / KEGG enrichment analysis of differentially expressed proteins in serum samples of healthy subjects and serum samples of patients with asymptomatic infection with Omicron.
[0035] Fig.10 This is the result of GO / KEGG enrichment analysis of differentially expressed proteins in serum samples of healthy subjects and symptomatic Omicron-infected subjects.
[0036] Fig.11 These are the results of GO / KEGG enrichment analysis of serum samples from patients with asymptomatic infection with Omicron and serum samples from patients infected with SARS-CoV-2.
[0037] Fig.12 These are the results of GO / KEGG enrichment analysis of serum samples from patients with symptomatic Omicron infection and serum samples from patients infected with SARS-CoV-2.
[0038] Fig.13 This is a protein network analysis of the differentially expressed proteins in asymptomatic Omicron infections and healthy humans. Figure A is the network diagram of the target protein, Figure B is the core pathway result diagram, Figure C is the GO enrichment analysis result, and Figure D is the KEGG enrichment analysis result.
[0039] Fig.14 This is a protein network analysis of the differentially expressed proteins in symptomatic Omicron infection and healthy humans. Figure A is the network diagram of the target protein, Figure B is the core pathway result diagram, Figure C is the GO enrichment analysis result, and Figure D is the KEGG enrichment analysis result.
[0040] Fig.15 This is a protein network analysis of the differentially expressed proteins in asymptomatic Omicron infections and SARS-CoV-2 infections. Figure A is the network diagram of the target protein, Figure B is the core pathway result diagram, Figure C is the GO enrichment analysis result, and Figure D is the KEGG enrichment analysis result.
[0041] Fig.16 This is a protein network analysis of the differentially expressed proteins in symptomatic Omicron infections and SARS-CoV-2 infections. Figure A is the network diagram of the target protein, Figure B is the core pathway result diagram, Figure C is the GO enrichment analysis result, and Figure D is the KEGG enrichment analysis result.
[0042] Fig.17 This is a heat map difference analysis of symptomatic and asymptomatic Omicron infections and healthy humans. Figure A is the result of the heat map difference analysis of asymptomatic Omicron infections and healthy humans, and Figure B is the result of the heat map difference analysis of symptomatic Omicron infections and healthy humans.
[0043] Fig.18 Figure 1 is the test result of the relative expression of VCL and ICAM-1 by RT-qPCR, wherein Figure A is the test result of the relative expression of VCL, and Figure B is the test result of the relative expression of ICAM-1.
[0044] Fig.19 This is a correlation comparison chart between VCL and infection-related indicators, CT scores, and core metabolites, among which Figure A shows asymptomatic patients with Omicron, Figure B shows patients with Omicron, and Figure C shows patients infected with SARS-CoV-2.
[0045] Fig. 20 This is the linear fitting curve of VCL protein in asymptomatic Omicron patients, where Figure A shows the correlation between VCL and CRP, and Figure B shows the correlation between VCL and CT score.
[0046] Fig.21Figure 1 is the linear fitting curve of VCL protein in symptomatic Omicron patients, where Figure A is the correlation result between VCL and CRP, Figure B is the correlation result between VCL and CT score, and Figure C is the correlation result between VCL and SAA.
[0047] Fig. 22 It is the linear fitting curve of VCL protein of patients with wild strain, among which Figure A is the correlation result between VCL and ICAM-1, Figure B is the correlation result between VCL and docosahexaenoic acid, Figure C is the correlation result between VCL and CRP, Figure D is the correlation result between VCL and PCT, Figure E is the correlation result between VCL and CT score, and Figure F is the correlation result between VCL and SAA.
[0048] Fig.23 It is a proteomic N-glycosylation heat map.
[0049] Fig.24 It is a structural prediction of VCL protein structure and N-glycosylation modification sites.
[0050] Fig.25 Figure 1 is the expression result of VCL and ICAM-1, wherein Figure A is the expression result of VCL, and Figure B is the expression result of ICAM-1.
[0051] Fig.26 Volcano plot of proteomic differences between Omicron patients and healthy controls.
[0052] Fig. 27 is the validation cohort heatmap.
[0053] Fig.28 It is the result of analyzing the glycosylation modification pathway.
[0054] Fig.29 It is a flow chart of animal modeling.
[0055] Fig.30 Figure 4 is the target protein level detection result, where Figure A is the VCL level detection result, Figure B is the ICAM-1 level detection result, Figure C is the HBP level detection result, and Figure D is the CRP level detection result.
[0056] Fig.31 This is the result of histological observation by HE staining.
[0057] Fig.32 The results are from the protein immunofluorescence assay to detect the distribution of cytoskeletal protein VCL.
[0058] Fig.33 This is the transmission electron microscopy observation result of the alveolar capillary barrier. Figure A shows the air-blood barrier structure under healthy conditions, and Figure B shows the lamellar bodies.
[0059] Fig.34 These are the results of transmission electron microscopy observations of the alveolar capillary barrier. Figure A shows the structure of the air-blood barrier under infection or inflammation, and Figure B shows the lamellar bodies.
[0060] Fig.35 These are the results of transmission electron microscopy observations of the alveolar capillary barrier. Figure A shows the results after lung injury and repair, and Figure B shows the lamellar bodies.
[0061] Fig.36 This is the microCT observation result of whole lung infiltration. DETAILED DESCRIPTION
[0062] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0063] Example 1
[0064] Detection of clinical characteristics of different groups of patients with COVID-19
[0065] Frozen serum samples were slowly thawed on ice. 400 μL of MeOH / CAN (1: 1, v / v) solvent mixture was added to each 100 μL serum (maintaining a ratio of 2: 2: 1 in the absence of water). Subsequently, the sample was vortexed on ice for 30 seconds and then sonicated on ice for 10 minutes using a high-intensity sonicator. The sample was then allowed to stand at -20°C for 1 hour and centrifuged at 4°C (12,000g, 15 minutes) to collect the supernatant, which was then dried at room temperature. 100 μL of CAN / H2O (1: 1, v / v) solvent mixture was added to the dried sample. The sample was vortexed on ice for 30 seconds and sonicated on ice for 10 minutes using a high-intensity sonicator. The mixture was then centrifuged at 4°C (12,000g, 15 minutes) to remove the precipitate. The supernatant was stored at -80°C prior to LC / MS analysis.
[0066] The results are as follows Figure 1-5 As shown in the figure, according to the clinical characteristics of the different groups of COVID-19 patients tested, they were compared with the healthy control group by statistical methods. It was found that the clinical manifestations and disease manifestations of patients in each group were different.
[0067] Example 2
[0068] The proteomics of the healthy control group, the asymptomatic group, the symptomatic group, and the SARS-CoV-2 infected group were analyzed and divided into the following groups: Figure 6 shown.
[0069] The analysis results are as follows Figure 7-12 As shown by Figure 7 It can be seen that the healthy control group has similar characteristics to the other three categories, while the asymptomatic patients have different characteristics from the symptomatic patients. The wild type has different characteristics from the other three categories, among which Figure 8 The Up region is a site with increased levels and significant differences, and the Down region is a site with decreased levels and significant differences. There are 51 differentially expressed proteins (17 downregulated and 34 upregulated) in the data of the asymptomatic infection group and the healthy control group. 62 differentially expressed proteins (24 downregulated and 38 upregulated) were identified in the data of symptomatic patients and the healthy control group, and 83 differentially expressed proteins (10 downregulated and 73 upregulated) were identified in the data of wild-type patients and the healthy control group. Compared with wild-type patients, asymptomatic patients had 82 differentially expressed proteins (54 downregulated and 28 upregulated), and symptomatic patients had 98 differentially expressed proteins (73 downregulated and 25 upregulated). There was almost no difference in the plasma proteome analysis of asymptomatic and symptomatic patients.
[0070] GO / KEGG enrichment analysis of differentially expressed proteins revealed multiple pathways associated with platelet response and vascular system damage in individuals infected with different virus strains. Differentially expressed proteins experienced vascular system damage in cellular component (CC), analytical function (MF) and major functional pathways of KEGG.
[0071] Example 3
[0072] Protein network analysis was performed on the differentially expressed proteins. By examining the interactions between protein genes, we can gain insight into the mechanisms of disease progression after infection with different virus strains. Figure 13-18 As shown. Figure 13-16 Figure A in the figure is the application of string tools to comb the network diagram of target proteins in proteomics, aiming to find the target protein pathway. Figure B is the application of Cytoscape tool cytoHubba plug-in to further refine the complex intertwined protein network in Figure A and find the core pathway. In the proteomic pathway analysis, the pathway with VCL as the core showed significant differences between the asymptomatic infection group of Omicron and the symptomatic infection group of Omicron. The comparison between SARS-CoV-2 infected patients and Omicron also found pathways related to immune inflammatory injury pathways and coagulation pathways, and VCL was also among them, indicating that pathways related to adhesion inflammation exudation coexist. In addition, the significant difference in the VCL pathway can also reflect that Omicron still retains the characteristic mechanism of inducing SARS-CoV-2 to cause lung exudation.
[0073] Heat map difference analysis of symptomatic and asymptomatic omegaly groups and healthy controls revealed that the VCL pathway was equally active in asymptomatic omegaly patients. Further testing by RT-qPCR confirmed the molecular signature of elevated VCL in SARS-CoV-2 patients. An increase in ICAM-1 was observed and it plays an adhesion role during the extravasation process.
[0074] Example 4
[0075] Correlation analysis of VCL in each disease group revealed that many other clinical inflammatory indicators and CT scores showed good correlation. Scatter plots can be used to visualize specific correlation parameters. Figure 19-25 As shown, Fig.19 Comparison of the correlation between VCL protein and clinical indicators. The farther from the central axis, the higher the correlation significance. For the correlation analysis between VCL as an exudation-inducing protein and the body's inflammatory state, there are some strong correlations between VCL and some clinical indicators related to inflammation. There is a significant positive correlation with the acute phase inflammatory protein SAA and CRP, and also a positive correlation with the lung exudate area shown by CT score, revealing the role of VCL pathway modification in inflammation, adhesion and extravasation function. Fig.23 Significant differences in the levels of N-glycosylated proteins were shown between healthy controls and COVID-19 patients. Significant differences in the levels of N-glycosylated proteins were found between healthy controls and COVID-19 patients, suggesting that changes in N-glycosylation may play a role in the development and progression of COVID-19. Fig.24 The Uniport online model is used to predict the structure of VCL protein and N-glycosylation modification sites.
[0076] Exploring the N-glycosylation level of the entire proteome, it was found that the N-glycosylation modification of VCL in COVID-19 patients showed a macroscopic gradual increase, from asymptomatic individuals to symptomatic individuals, and then to WT patients, showing a significant linear increase. In contrast, the N-glycosylation level of ICAM-1 decreased linearly.
[0077] Example 5
[0078] Verify the results
[0079] The validation analysis reduces the errors caused by batch effects. The results are as follows Figure 26-28 As shown, Fig.26 The Up region is a site with increased levels and significant differences, and the Down region is a site with decreased levels and significant differences. The statistical results showed that VCL showed a significant upward trend in the Omicron patient group (P<0.001). Fig. 27It was also shown that Omicron infection resulted in significant changes in protein abundance. These changes may be associated with the pathological mechanisms of viral infection. Further studies are needed to determine the specific roles of these differentially expressed proteins and identify new targets for the treatment and diagnosis of Omicron infection. Fig.28 The GO clustering analysis method was used to analyze the N-glycosylation modification pathway, and it was found that acute inflammation, vesicle release and intercellular connection were significant, and were closely related to the function of the target protein VCL.
[0080] The changes in VCL and ICAM-1 levels associated with extravasation caused by the current Omicron subvariant infection were confirmed, the differences in VCL and ICAM-1 expression observed in the proteomic analysis were consistent and independent of the batch effect, and GO / KEGG pathway enrichment analysis showed that the differentially expressed proteins were significantly enriched in pathways related to acute inflammation and structural proteins.
[0081] Example 6
[0082] Experimental method reference Fig.29 .
[0083] Specifically, this study established a corresponding rat lung injury model experiment. Due to the high infectivity of the Omicron strain and the laboratory conditions required, live virus experiments could not be performed in the early stage under limited conditions. In order to simulate the lung exudation-injury effect, lipopolysaccharide (LPS) was used for modeling in the study. SD rats were used as the research subjects, the control group included 10 healthy rats treated with normal saline, the lung injury model (Control) group had 20 rats, and the intervention group (Intervention) included 10 rats treated with Anti-VCL and 10 rats in the no-intervention group (No-intervention).
[0084] The results are shown in 30-36. Fig.30 It can be seen that the PCR technology of the lung injury animal model detected the level of the target protein VCL. It can be seen that the VCL level in the non-intervention group increased significantly, while the VCL level in the intervention group decreased significantly. Serum analysis showed that the levels of VCL, ICAM-1, HBP, and CRP in the lung injury model group increased significantly, and decreased after intervention.
[0085] Figure 33-35 Results of observation of blood-gas barrier in mice by transmission electron microscopy. Fig.33 Figure A shows the structure of the air-blood barrier under normal conditions, showing that the respiratory membrane has uniform thickness and a complete and continuous structure. Figure B shows lamellar bodies with visible lamellar structures. Fig.34 Figure A shows that under infection or inflammation conditions, the pulmonary air-blood barrier is destroyed, the continuity of the respiratory membrane is interrupted, the matrix and gliosis, and the pulmonary interstitium proliferate. Figure B shows that the lamellar bodies are consumed. Fig.35 Figure A shows the structure of the air-blood barrier after lung injury repair. The respiratory membrane has returned to normal structure, but the underlying pulmonary interstitial fibrosis still exists. Figure B shows the lamellar bodies, which have returned to normal structure. In the case of injury, the surfactant membrane of the alveolar epithelium is damaged, and the basal layer is disordered and thickened. In B, the lamellar bodies are consumed. From this, we can assume that changes in VCL may also be accompanied by damage to the alveolar structure.
[0086] Transmission electron microscopy of mice to observe the air-blood barrier. A. The lung structure was repaired after injury. The air-blood barrier structure was restored, but fibrosis was still retained. B. The lamellar bodies were restored. The decrease in VCL levels was consistent with the repair of alveolar structure.
[0087] Using HE staining histological examination, it was found that there were tissue differences between healthy mice and model mice. After Anti-VCL intervention, alveolar edema was alleviated, but some alveoli were not fully expanded and the interstitium was still thickened. Further analysis of the alveolar capillary barrier information in HE-stained sections showed that the respiratory membrane in the lung injury group was severely damaged. Even after intervention, the interstitium was still filled with a large number of fibroblasts, resulting in abnormal alveolar structure, which may be one of the reasons for incomplete recovery of lung function. Protein immunofluorescence was used to detect the distribution of cytoskeletal protein VCL. It can be found that VCL expression increased significantly during lung injury, indicating that cell activity increased in the inflammatory environment. The distribution of VCL can clearly outline the alveolar structure and its presence was not observed in the edema fluid, indicating that VCL is an important supporting protein for the alveolar cytoskeleton structure. The alveolar capillary barrier was observed using a transmission electron microscope. The normal respiratory membrane structure and the structure in lung injury tissue were observed. It was also found that after Anti-VCL intervention, the respiratory membrane structure basically returned to normal. The exudation of the whole lung was observed by microCT, indicating that anti-VCL (inhibitor injection) treatment brought significant improvement.
[0088] The applicant declares that the present invention illustrates a marker and application for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0089] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0090] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, characterized in that: The markers include VCL and / or ICAM-1.
2. Use of the marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 according to claim 1 or the reagent for detecting the expression amount of the marker according to claim 1 in the preparation of a product for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2.
3. The use according to claim 2, characterized in that: The application includes constructing a prediction or diagnosis model for SARS-CoV-2-induced inflammatory damage to the air-blood barrier and / or preparing a prediction or diagnosis device for predicting or diagnosing SARS-CoV-2-induced inflammatory damage to the air-blood barrier.
4. A product for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, characterized in that: The product comprises a reagent and / or a device for detecting the relative expression level of the marker according to claim 1.
5. The product for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 according to claim 4, characterized in that: The products include kits.
6. A prediction or diagnosis model for inflammatory damage to the air-blood barrier caused by SARS-CoV-2, characterized in that: The input variables of the prediction or diagnosis model of inflammatory damage to the air-blood barrier caused by SARS-CoV-2 include the expression level of the marker for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 as described in claim 1.
7. The prediction or diagnosis model of inflammatory damage to the air-blood barrier caused by SARS-CoV-2 according to claim 6, characterized in that: The output variables of the prediction or diagnosis model of SARS-CoV-2-induced air-blood barrier inflammatory damage include differential expression folds, The calculation formula of the differential expression fold is as follows:
8. The prediction or diagnosis model of inflammatory damage to the air-blood barrier caused by SARS-CoV-2 according to claim 7, characterized in that: The criteria for judging inflammatory damage to the air-blood barrier caused by SARS-CoV-2 are: The differential expression fold of the VCL is ≥1, and the differential expression fold of the ICAM-1 is ≥1.
9. A device for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2, characterized in that: The device comprises a detection unit and an analysis unit; The detection unit is used to perform the following steps: detecting the expression level of a combination of biomarkers for predicting or diagnosing inflammatory damage to the air-blood barrier caused by SARS-CoV-2 in a sample of an individual to be tested; The analysis unit is used to perform the following steps: The detection results of the biomarkers used to predict or diagnose SARS-CoV-2-induced inflammatory damage to the air-blood barrier are input into the prediction or diagnosis model for SARS-CoV-2-induced inflammatory damage to the air-blood barrier described in any one of claims 6 to 8 for data analysis, and the prediction probability is output to determine whether the SARS-CoV-2-induced inflammatory damage to the air-blood barrier is positive.
10. The device according to claim 9, characterized in that The sample includes serum.
